Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis c virus genotype 1 infection

Gastroenterology

Volumn 145, Issue 4, 2013, Pages

  Marcellin, Patrick ^a   Cooper, Curtis ^b   Balart, Luis ^c   Larrey, Dominique ^d   Box, Terry ^e   Yoshida, Eric ^f   Lawitz, Eric ^g   Buggisch, Peter ^h   Ferenci, Peter ⁱ   Weltman, Martin ^j   Labriola Tompkins, Emily ^k   Le Pogam, Sophie ^k   Nájera, Isabel ^k   Thomas, Denise ^l   Hooper, Gregory ^l   Shulman, Nancy S ^m   Zhang, Ying ^m   Navarro, Mercidita T ^m   Lim, Chin Yin ^m   Brunda, Michael ^k   Terrault, Norah A ⁿ   Yetzer, Ellen S ^m   more..

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITY OF OTTAWA   (Canada)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIV MONTPELLIER   (France)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g Alamo Medical Research   (United States)

^h DEPARTMENT OF CARDIOLOGY   (Germany)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j NEPEAN HOSPITAL   (Australia)

^k HOFFMANN LA ROCHE INC   (United States)

^l ROCHE PRODUCTS LTD   (United Kingdom)

^m GENENTECH INC   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Danoprevir (RG7227) Hepatitis C Virus Sustained Virologic Response Response Guided Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; DANOPREVIR; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CHILL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS RESISTANCE; VOMITING;

EID: 84884411153     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.06.051     Document Type: Article

References (26)

1. M.G. Ghany, D.R. Nelson, and D.B. Strader An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
2. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
3. F. Poordad, J. McCone Jr., and B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
4. K.E. Sherman, S.L. Flamm, and N.H. Afdhal Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
5. Incivek [prescribing information] October 2012 Vertex Pharmaceuticals Inc. Cambridge, MA
6. Victrelis [prescribing information] November 2012 Merck and Co. Whitehouse Station, NJ
7. J.M. Gottwein, T.K. Scheel, and T.B. Jensen Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses Gastroenterology 141 2011 1067 1079
8. I. Imhof, and P. Simmonds Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191) Hepatology 53 2011 1090 1099
9. E.J. Gane, S.K. Roberts, and C.A. Stedman Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
10. N. Forestier, D. Larrey, and D. Guyader Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study J Hepatol 54 2011 1130 1136
11. N. Forestier, D. Larrey, and P. Marcellin Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C J Infect Dis 204 2011 601 608
12. D. Larrey, C. Carenco, and D. Guyader Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon α-2a (40 KD) plus ribavirin Antiviral Ther 17 2012 927 932
13. Division of AIDS table for grading the severity of adult and pediatric adverse events. Version 1.0, December 2004; clarification August 2009. Available at: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table-for- Grading-Severity-of-Adult-Pediatric-Adverse-Events.pdf. Accessed November 21, 2012.
14. S. Le Pogam, A. Seshaadri, and A. Kosaka Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients J Antimicrob Chemother 61 2008 1205 1216
15. E.B. Wilson Probable inference, the law of succession, and statistical inference J Am Stat Assoc 22 1927 209 212
16. R.G. Newcombe Two-sided confidence intervals for the single proportion: comparison of seven methods Stat Med 17 1998 857 872
17. M. Levi High exposure to danoprovir (RG7227) increases the probability of ALT elevations in patients treated with danoprevir plus PegIFN a-2a (40KD) (PEGASYS) plus ribavirin Hepatology 52 Suppl 1 2010 1216A
18. E.J. Gane, R. Rouzier, and C. Stedman Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients J Hepatol 55 2011 972 979
19. P. Goelzer, P. Morcos, and J. Tran Ritonavir substantially reduces reactive metabolite formation of the HCV protease inhibitor danoprevir both in vitro and in vivo J Hepatol 56 Suppl 2 2012 S467
20. G. Everson, C. Cooper, and C. Hézode High SVR24 rates with ritonavir-boosted danoprevir plus Peg-IFNα-2a (40KD)/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study Hepatology 56 Suppl 1 2012 552A
21. J.J. Feld, I.M. Jacobson, and D.M. Jensen Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) ± peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study Hepatology 56 Suppl 1 2012 231A
22. N.M. Dabbouseh, and D.M. Jensen Future therapies for chronic hepatitis C Nat Rev Gastroenterol Hepatol 10 2013 268 276
23. E.J. Gane, P. Pockros, and S. Zeuzem Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naive HCV genotype 1-infected patients J Hepatol 56 Suppl 2 2012 S555
24. I.M. Jacobson, I. Catlett, and P. Marcellin Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial J Hepatol 54 Suppl 1 2011 S542 S543
25. S. Beinhardt, A.F. Staettermayer, and K. Rutter Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias? Hepatology 55 2012 30 38
26. L. Vijgen, W. Talloen, and A. Scholliers Pre-treatment IP-10 levels and IL28B genotype in prediction of SVR in prior treatment-experienced genotype 1 HCV patients treated with telaprevir/peginterferon/ribavirin in the REALIZE study J Hepatol 56 Suppl 2 2012 S462